Results for flare ups translation from English to Maltese

flare up of old infections
re-attivazzjoni ta’ infezzjonijiet tal-passat

relapsing means that the patient has flare-ups of the symptoms.
reċidivanti tfisser li l-pazjent ikollu taħrix f'daqqa tas-sintomi.

relvar ellipta has been shown to reduce flare-ups of copd symptoms.
relvar ellipta ntwera li jnaqqas it-tifqigħat tas-sintomi ta’ copd.

symptoms of infection and inflammation old infections may flare up
sintomi ta’ infezzjoni u infjammazzjoni infezzjonijiet tal-passat jistgħu jerġgħu joħorġu

the main measure of effectiveness was the number of flare-ups the patients had over a year.
il-kejl prinċipali tal- effikaċja kien in-numru ta’ żidiet f’daqqa li kellhom il-pazjenti matul sena.

chronic obstructive pulmonary disease (copd), to reduce the number of flare ups of symptoms.
marda kronika ostruttiva tal-pulmun (copd - chronic obstructive pulmonary disease), biex tnaqqas in- numru ta’ taħrix tas-sintomi.

relvar ellipta at all strengths was more effective in reducing the number of copd flare-ups than vilanterol alone.
relvar ellipta fil-qawwiet kollha kien aktar effikaċi fit-tnaqqis tal- għadd ta’ flare-ups ta’ copd minn vilanterol waħdu.

ms also tends to flare up from time to time: this is called a relapse.
ms għandha tendenza li tiggrava minn ħin għal ieħor: dan jissejjaħ irkadar.

cinqaero reduces how often you have flare-ups of your asthma, helps you breathe better and decreases your asthma symptoms.
cinqaero jnaqqas kemm-il darba inti jkollok irkadar tal-ażżma tiegħek, jgħinek tieħu n-nifs aħjar, u jnaqqas is-sintomi tal-ażżma tiegħek.

protopic can also be used to prevent flare-ups of the disease or prolong the time that patients are free from flare-ups.
protopic jista’ jintuża wkoll għall-prevenzjoni ta’ żidiet f’daqqa tal-marda jew biex itawwal iż-żmien li l- pazjenti ma jkollhomx żidiet f’daqqa.

for some people, gout attacks may flare up when starting certain medicines that control uric acid levels.
għal xi persuni, attakki tal-gotta jistgħu jirkadaw meta jinbdew ċertu mediċini li jikkontrollaw il- livelli ta’ uric acid.

a flare-up of symptoms related to an inactive infection in your body (immune reactivation);
aggravar ta’ sintomi relatati ma infezzjoni mhux attiva fil-ġisem (riattivazzjoni immunitarja)

it could flare up again in response to poorly conceived new requirements, interference with research work, and additional red tape.
din l-iskuntentizza tista’ terġa’ tiżbroffa minħabba n-nuqqas ta’ ħsieb fit-tfassil tar-rekwiżiti ġodda, l-indħil fil-ħidma ta’ riċerka u l-ostakli burokratiċi ġodda.

when the symptoms flare up, it is called a relapse (also known as an exacerbation or an attack).
meta s-sintomi jiżdiedu, din tissejjaħ rikaduta (magħrufa wkoll bħala taħrix tal-marda jew attakk).

in copd, aerivio spiromax is used in adults who have had exacerbations (flare–ups) of the disease in the past and have significant symptoms despite regular treatment.
f’copd, aerivio spiromax jintuża f’adulti li fil-passat kellhom aggravar tal-marda u li għandhom sintomi sinifikanti minkejja kura regolari.

the reduction in flare-ups and improvement in lung function seen with cinqaero were considered clinically relevant, particularly for patients who cannot be adequately controlled with high doses of inhaled corticosteroids and another medicine used for the prevention of asthma.
it-tnaqqis fir-rikaduti u t-titjib fil-funzjoni tal-pulmun li dehru b'cinqaero tqiesu bħala klinikament rilevanti, b'mod partikolari għall-pazjenti li ma jistgħux jiġu kkontrollati b'mod adegwat b'dożi għolja ta' kortikosterojdi li jittieħdu man-nifs u b'mediċina oħra li tintuża għall-prevenzjoni tal-ażma.

7% of the individuals with ad in clinical trials with imvanex experienced a flare-up or worsening of their skin condition during the course of the trial.
7% tal-individwi b’ad fil-provi kliniċi b’imvanex kellhom aggravament f’daqqa jew aggravament tal- kundizzjoni tal-ġilda tagħhom matul il-kors tal-prova.

patients with relapsing-remitting ms have periods when the disease is not active (remission) in between flare-ups of symptoms (relapses).
pazjenti b’ms li tirkadi u tbatti jkollhom perjodi fejn il-marda ma tkunx attiva (remissjoni) bejn l-aggravamenti tas-sintomi (rikaduti).

data from this study showed that 12.8% of patients taking revinty ellipta had one or more severe flare-ups by 52 weeks compared with 15.9% of patients taking fluticasone furoate alone.
dejta minn dan l-istudju wriet li 12.8% tal-pazjenti li ħadu revinty ellipta kellhom żieda f’daqqa severa waħda jew aktar sa 52 ġimgħa wara meta mqabbla ma’ 15.9% tal-pazjenti li ħadu fluticasone furoate waħdu.

flare-ups were seen in 32% of patients (151 out of 477) given cinqaero compared with 50% (237 out of 476) of those given placebo.
ir-rikaduti dehru fi 32 % tal- pazjenti (151 minn 477) li ngħataw cinqaero meta mqabbla ma' 50 % (237 minn 476) ta' dawk li ngħataw plaċebo.